Clinical Trial

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the objective response of GB1211 and pembrolizumab versus pembrolizumab and placebo in patients with advance metastatic melanoma or head and neck squamous cell carcinoma.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-06-19; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting 2024-03-26
Trial Details
NCT Number NCT05913388
Lead Sponsor Providence Health & Services
Collaborators: Providence Cancer Center, Providence Cancer Center, Earle A. Chiles Research Institute, Galecto Biotech AB
Conditions Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
Enrollment 92 participants
Start Date 2024-02-29
Primary Completion 2028-02 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-04-13